挪威特种生化企业博瑞格（Borregaard ASA）披露2025年第二季度财务报告，营运收入同比增长4.9%至20.45亿挪威克朗（上年同期19.49亿克朗）。息税折旧摊销前利润（EBITDA）达5.22亿克朗，较去年同期的5.10亿克朗稳步提升。税前利润微增至3.26亿克朗（上年3.22亿克朗），每股收益由2.45克朗攀升至2.56克朗。
两大核心业务板块展现强劲动能：生物解决方案部门受益于农业领域销售增长，生物材料部门则在木材成本上升的背景下，凭借产品售价提升、结构优化及销量扩张实现业绩突破。与之相对，精细化学品部门受生物乙醇价格下行拖累表现疲软。外汇波动对所有业务板块均产生正向影响。
首席执行官佩尔·A·索利指出："生物材料板块特种纤维素涨价策略成效显著，生物解决方案领域农业需求的强劲增长，共同构成了本季业绩双引擎。"公司股价在奥斯陆交易所早盘交易中应声上涨2.3%。
（注：本简报基于博瑞格通过环球新闻专线发布的原始公告编制，公告编号GNW1001118082-en，发布日期2025年7月16日。内容仅供参考，不构成任何投资建议。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.